Menu Search
Equities

Kiora Pharmaceuticals Inc

7EY0:DUS

Kiora Pharmaceuticals Inc

Actions
  • Price (EUR)0.4955
  • Today's Change0.009 / 1.85%
  • Shares traded1.25k
  • 1 Year change-74.03%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 18:32 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).

  • Revenue in USD (TTM)16.00m
  • Net income in USD2.28m
  • Incorporated2004
  • Employees12.00
  • Location
    Kiora Pharmaceuticals Inc332 ENCINITAS BOULEVARD, SUITE 102ENCINITAS 92024United StatesUSA
  • Phone+1 (781) 788-8869
  • Fax+1 (302) 636-5454
  • Websitehttps://kiorapharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.